This might be the reason...
BW1330 JUL 14,1997 8:23 PACIFIC 11:23 EASTERN
( BW)(VASOMEDICAL)(VASO) Vasomedical announces installation of first unit
in Japan
Business/Health Editors & Medical Writers
WESTBURY, N.Y--(BW HealthWire)--July 14, 1997--In a follow-up to
an earlier release, Vasomedical, (NASDAQ:VASO;
vasomedical.com), is pleased to announce that it has installed
its first EECP(R) unit in Japan at Kyoto University Hospital.
Patient treatment has already begun.
The installation in Kyoto represents the first of three sites
that will be set up to conduct the necessary clinical trials for
Japanese regulatory and reimbursement approvals. Additional units
are expected to be installed in August and October.
The Japanese market represents a substantial opportunity for
Vasomedical and EECP(R). What makes EECP(R) especially attractive
to physicians and patients is the noninvasive nature of the
treatment. As a viable alternative to bypass surgery and balloon
angioplasty, EECP(R) provides another option in the cardiac care
continuum. Once all approvals have been received, Vasomedical
expects to sell eight units in Japan in the first year of operation.
EECP(R) is a noninvasive treatment for patients with coronary
artery disease. It is marketed internationally to hospitals,
clinics, and other cardiac care providers.
Vasomedical is a medical technology company devoted to the
development, manufacture and commercialization of innovative and
cost-effective cardiovascular products.
Except for historical information contained in this news release,
the matters discussed are forward looking statements that involve
risks and uncertainties. Among the factors that could cause actual
results to differ materially are the following: the effect of
business and economic conditions; the impact of competitive products
and pricing; capacity and supply constraints or difficulties; product
development, commercialization or technological difficulties; the
regulatory and trade environments; and the risk factors reported from
time to time in the Company's SEC reports.
--30--kam/ny* rc
CONTACT: Vasomedical Inc., Westbury
Natalie Karp, 516/997-4600 ext. 776
KEYWORD: NEW YORK
INDUSTRY KEYWORD: MEDICINE PHARMACEUTICAL BIOTECHNOLOGY
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com |
